Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We conducted a 3-year open-label extension of a 2-year randomized, placebo-controlled, double-blind study....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CMAJ
Autors principals: Grey, Andrew, Bolland, Mark J., Horne, Anne, Mihov, Borislav, Gamble, Greg, Reid, Ian R.
Format: Artigo
Idioma:Inglês
Publicat: Joule Inc. 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595552/
https://ncbi.nlm.nih.gov/pubmed/28893875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/cmaj.161207
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars